The Putative Effects of Neoadjuvant Chemotherapy on the Immune System of Advanced Epithelial Ovarian Carcinoma

被引：1
作者：
Li, Yunyun [1 ,2 ]
Gan, Xiaoling [2 ]
Li, Fei [1 ]
Hu, Lina [2 ,3 ]
机构：
[1] Chongqing Med Univ, Dept Gynecol & Obstet, Yongchuan Hosp, Chongqing, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 2, Dept Gynecol, Chongqing, Peoples R China
[3] Chongqing Med Univ, Dept Gynecol & Obstet, Affiliated Hosp 2, 288 Tianwen Rd, Chongqing, Peoples R China
来源：
IMMUNOLOGICAL INVESTIGATIONS | 2024年 / 53卷 / 02期
关键词：
Epithelial ovarian cancer (EOC); immune reactive; immune suppressive; interval debulking surgery (IDS); neoadjuvant chemotherapy (NACT); tumor immune microenvironment (TME); REGULATORY T-CELLS; DENDRITIC CELLS; CANCER; TRIAL; MICROENVIRONMENT; RECURRENCE; TOLERANCE; FREQUENCY; SURGERY;
D O I：
10.1080/08820139.2023.2284885
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The epithelial ovarian carcinoma (EOC) is one of leading causes of cancer-related mortality in females. For some patients, complete resection cannot be achieved, thus neoadjuvant chemotherapy (NACT) following interval debulking surgery (IDS) could be an alternative choice. In general-held belief, cytotoxic chemotherapy is assumed to be immunosuppressive, because of its toxicity to dividing cells in the bone marrow and peripheral lymphoid tissues. However, increasing evidence highlighted that the anticancer activity of chemotherapy may also be related to its ability to act as an immune modulator. NACT not only changed the morphology of cancer cells, but also changed the transcriptomic and genomic profile of EOC, induced proliferation of cancer stem-like cells, gene mutation, and tumor-related adaptive immune response. This review will provide a comprehensive overview of recent studies evaluating the impact of NACT on cancer cells and immune system of advanced EOC and their relationship to clinical outcome. This information could help us understand the change of immune system during NACT, which might provide new strategies in future investigation of immuno-therapy for maintenance treatment of EOC.
引用
收藏
页码：91 / 114
页数：24
相关论文
共 70 条
[1]   Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival [J].
Alberts, David S. ;
Marth, Christian ;
Alvarez, Ronald D. ;
Johnson, Gary ;
Bidzinski, Mariusz ;
Kardatzke, David R. ;
Bradford, Williamson Z. ;
Loutit, Jeff ;
Kim, David H. ;
Clouser, Mary C. ;
Markman, Maurie .
GYNECOLOGIC ONCOLOGY, 2008, 109 (02) :174-181
[2]   Advances in Ovarian Cancer Treatment Beyond PARP Inhibitors [J].
Aliyuda, Fine ;
Moschetta, Michele ;
Ghose, Aruni ;
Rallis, Kathrine Sofia ;
Sheriff, Matin ;
Sanchez, Elisabet ;
Rassy, Elie ;
Boussios, Stergios .
CURRENT CANCER DRUG TARGETS, 2023, 23 (06) :433-446
[3]   Mast Cells in the Tumor Microenvironment [J].
Aponte-Lopez, Angelica ;
Munoz-Cruz, Samira .
TUMOR MICROENVIRONMENT: HEMATOPOIETIC CELLS, PT B, 2020, 1273 :159-173
[4]   Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC [J].
Arend, Rebecca C. ;
Scalise, Carly B. ;
Gordon, Emily R. ;
Davis, Allison M. ;
Foxall, McKenzie E. ;
Johnston, Bobbi E. ;
Crossman, David K. ;
Cooper, Sara J. .
CLINICAL CANCER RESEARCH, 2022, 28 (07) :1433-1445
[5]   Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma [J].
Arend, Rebecca C. ;
Londono, Angelina I. ;
Montgomery, Allison M. ;
Smith, Haller J. ;
Dobbin, Zachary C. ;
Katre, Ashwini A. ;
Martinez, Alba ;
Yang, Eddy S. ;
Alvarez, Ronald D. ;
Huh, Warner K. ;
Bevis, Kerri S. ;
Straughn, J. Michael, Jr. ;
Estes, Jacob M. ;
Novak, Lea ;
Crossman, David K. ;
Cooper, Sara J. ;
Landen, Charles N. ;
Leath, Charles A., III .
MOLECULAR CANCER RESEARCH, 2018, 16 (05) :813-824
[6]   Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity [J].
Bakos, Orneala ;
Lawson, Christine ;
Rouleau, Samuel ;
Tai, Lee-Hwa .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[7]   Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape [J].
Blanc-Durand, Felix ;
Genestie, Catherine ;
Galende, Elisa Yaniz ;
Gouy, Sebastien ;
Morice, Philippe ;
Pautier, Patricia ;
Maulard, Amandine ;
Mesnage, Soizick ;
Le Formal, Audrey ;
Brizais, Chloe ;
Richardson, Michael ;
Leary, Alexandra .
GYNECOLOGIC ONCOLOGY, 2021, 160 (01) :279-284
[8]   Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma [J].
Bohm, Steffen ;
Montfort, Anne ;
Pearce, Oliver M. T. ;
Topping, Joanne ;
Chakravarty, Probir ;
Everitt, Gemma L. A. ;
Clear, Andrew ;
McDermott, Jackie R. ;
Ennis, Darren ;
Dowe, Thomas ;
Fitzpatrick, Amanda ;
Brockbank, Elly C. ;
Lawrence, Alexandra C. ;
Jeyarajah, Arjun ;
Faruqi, Asma Z. ;
McNeish, Iain A. ;
Singh, Naveena ;
Lockley, Michelle ;
Balkwill, Frances R. .
CLINICAL CANCER RESEARCH, 2016, 22 (12) :3025-3036
[9]   BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside [J].
Boussios, Stergios ;
Rassy, Elie ;
Moschetta, Michele ;
Ghose, Aruni ;
Adeleke, Sola ;
Sanchez, Elisabet ;
Sheriff, Matin ;
Chargari, Cyrus ;
Pavlidis, Nicholas .
CANCERS, 2022, 14 (16)
[10]   Combining DNA damaging therapeutics with immunotherapy: more haste, less speed [J].
Brown, Jessica S. ;
Sundar, Raghav ;
Lopez, Juanita .
BRITISH JOURNAL OF CANCER, 2018, 118 (03) :312-324
1234567